Heart-Rate Recovery at 1 Min After Exercise Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Yi Zhang†, Xin Li†, Qin Luo†, Qing Zhao†, Qixian Zeng†, Tao Yang†, Qi Jin†, Lu Yan†, Anqi Duan†, Xiuping Ma†, Chenhong An†, Changming Xiong†, Zhihui Zhao* and Zhihong Liu**

†Center for Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ‡Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

Background: Dysfunction of autonomic nervous system plays an important role in the development of pulmonary hypertension. The present study aimed to investigate the interaction between balloon pulmonary angioplasty (BPA) and cardiac autonomic function by using heart-rate recovery at 1 min (HRR1) after exercise as a surrogate marker.

Methods and Results: We retrospectively enrolled 89 consecutive patients with inoperable chronic thromboembolic pulmonary hypertension who underwent BPA from May, 2018 to Jan, 2021. According to hemodynamics at follow-up, patients were categorized as BPA responders if they met one or both of the following criteria: (1) mean pulmonary arterial pressure \( \leq \) 30 mmHg and (2) a reduction of pulmonary vascular resistance \( \geq \) 30%. Compared with baseline, HRR1 tended to increase within 7 days after the first BPA session, and this improvement persisted at follow-up. HRR1 at baseline and at follow-up were associated with well-validated markers of CTEPH severity, including N-terminal pro-brain natriuretic peptide, mean pulmonary arterial pressure and pulmonary vascular resistance. Furthermore, the change of HRR1 from baseline to follow-up was also associated with the change of those variables. After adjustment for confounders, baseline HRR1 was still a strong independent predictor of BPA outcome. Receiver operator characteristic curve analysis showed that the cutoff value for HRR1 in predicting BPA outcome was 19 beats.

Conclusions: BPA could significantly improve HRR1, suggesting the alleviation of sympathovagal imbalance. Easily available and non-invasive HRR1 seems to be a useful tool in predicting outcome of BPA and dynamically monitoring the efficacy of BPA.

Keywords: chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty, heart-rate recovery at 1 min, cardiac autonomic function, prognosis
INTRODUCTION

Chronic thromboembolic pulmonary hypertension (CTEPH) is featured by organized chronic thrombi in proximal or distal pulmonary arteries and small-vessel remodeling in non-occluded areas, which increases pulmonary arterial pressure and results in right-sided heart failure (1). The prognosis of CTEPH is poor, with a 5-year survival rate of 10% for patients with a mean pulmonary arterial pressure (mPAP) > 50 mmHg (2).

Currently, pulmonary endarterectomy is the first therapeutic option for CTEPH (3). However, as many as 40% of patients are ineligible for surgical intervention due to reasons like severe comorbidities, distal lesions, and other patient specific factors (4, 5). Over the past decade, refined balloon pulmonary angioplasty (BPA) is emerging as an alternative option for inoperable CTEPH. Increasing evidences suggest that BPA could significantly improve hemodynamics, exercise tolerance and pulmonary function (6, 7).

Sympathetic, parasympathetic, and sensory nerve fibers innervate the pulmonary vasculature (8). In general, sympathetic nerve stimulation causes vasoconstriction of pulmonary vasculature and vagal stimulation results in vasodilation. Dysfunction of autonomic nervous system plays an important role in the development of pulmonary hypertension (8, 9). Moreover, it has been demonstrated that pulmonary artery denervation could improve the hemodynamics and exercise capacity of patients with pulmonary hypertension (10–13).

Heart-rate recovery at 1 min (HRR1) after exercise is a widely recognized surrogate marker of cardiac autonomic function, which is defined as the change in heart rate (HR) from the maximum workload to 60 s after exercise cession (14). HRR1 is a non-invasive and less time-consuming measure, which can be quickly obtained from routine exercise testing [cardiopulmonary exercise test (CPET) or 6-min walk test], compared with other HR responses, such as HR variability measured with Holter electrocardiography. Previous studies have reported that HRR1 was associated with exercise tolerance, hemodynamics and prognosis in patients with pulmonary arterial hypertension (PAH) (group I pulmonary hypertension) (15–17). Additionally, Inagaki et al. also reported that HRR1 was correlated with hemodynamics in CTEPH (group IV pulmonary hypertension) (18). Recently, we reported that HRR1 could independently predict prognosis in patients with CTEPH (19). However, to the best of our knowledge, no one has systematically studied the interaction between BPA and cardiac autonomic function. The main objectives of the present study were to determine whether BPA could alleviate sympathovagal imbalance and whether baseline HRR1 could predict outcome of BPA.

MATERIALS AND METHODS

Study Design and Participants
This retrospective study was conducted in Fuwai Hospital, Chinese Academy of Medical Sciences (Beijing, China). The study protocol was approved by the Ethics Committee of Fuwai Hospital (Approval NO: 2020-1275). Written informed consent was obtained from each patient. We screened all patients with inoperable CTEPH who underwent BPA from May, 2018 to Jan, 2021. The establishment of CTEPH was based on the 2015 European Society of Cardiology/European Respiratory Society guidelines (4). The eligibility for BPA was assessed by a multidiscipline team, consisting of a surgeon specializing in pulmonary endarterectomy, an interventional cardiologist specializing in BPA and a physician specializing in pulmonary hypertension. By design, patients were excluded if they: (1) did not have baseline HRR1 data; (2) did not undergo right heart catheterization (RHC) at follow-up; (3) were using beta-blockers or other antiarrythmic agents. The following clinical data were collected via an electronic medical record system by two independent reviewers: demographics, World Health Organization functional class (WHO-FC), N-terminal pro-brain natriuretic peptide (NT-proBNP), arterial oxygen saturation ($S_{O_2}$), 6-min walk distance (6MWD), targeted therapy at baseline, anticoagulants, parameters derived from echocardiography, CPET and RHC, the number of BPA sessions, the number of dilated subsegmental vessels, and the time interval between baseline and reevaluation RHC. Any discordance was resolved by the supervisors (ZHZ and ZHL).

RHC and BPA Procedure
In our center, a single catheterization laboratory visit consists of one BPA session and two RHC measurement. The first RHC measurement was performed before the initiation of BPA procedure to acquire the baseline hemodynamics. The second RHC measurement was performed immediately after the BPA procedure to acquire immediate post-operative hemodynamics. The detailed protocols of RHC and BPA have been provided in our previous publications (20, 21). Briefly, RHC was performed to measure hemodynamics, including mixed venous oxygen saturation, right atrial pressure, right ventricular pressure, mPAP, pulmonary arterial wedge pressure (PAWP), cardiac output (calculated by Fick’s method) and pulmonary vascular resistance (PVR). After RHC, we performed pulmonary angiography, in anterior-posterior and lateral (60 degree) projections, to acquire overall view of the filling defect. Subsequently, a 70 cm 6F-7F long sheath (Flexor® Check-Flo® Introducer; Cook Medical, Bloomington, IN, USA), via the right femoral vein, was inserted into the lobar pulmonary artery to introduce a 6F guiding catheter (Multi-purpose [Cordis Corporation, Bridgewater, New Jersey, USA] or Amplatz Left [Terumo® Heartrail™ II; Terumo Corporation, Tokyo, Japan] or Judkins Right Tokyo, Japan) or Judkins Right [Terumo® Heartrail™ II; Terumo Corporation, Tokyo, Japan]). Based on selective pulmonary angiography, a 0.014-inch guidewire (Hi-Torque Pilot 50; Abbot, Santa Clara, CA, USA) was passed across the target lesion. To reduce the risk of complications, a 2.0 × 20 mm balloon was used at initial dilation, while smaller balloons may also be used for subtotal or total occlusion lesions. The balloon size was gradually increased in the subsequent BPA sessions according to the reference vessel diameter. Inflation pressure was dynamically adjusted, and selective angiography was performed to confirm vascular filling. Assessment of WHO-FC, NT-proBNP, $S_{O_2}$, 6MWD, echocardiography and CPET were performed within 7 days prior to and after each BPA procedure. Follow-up reevaluation,
including RHC and CPET, would be performed over 3 months after the last BPA session.

Cardiopulmonary Exercise Test
The detailed protocols of CPET have been provided in our previous publications (22, 23). Briefly, an incremental symptom-limited exercise test was performed by the same examiner on an upright cycle ergometer using the COSMED Quark CPET system (COSMED, Rome, Italy). Three minutes of rest were followed by 3 min of unloaded pedaling, and progressively increasing workload by 5–10 W/min in a ramp pattern to maximum tolerance. HRR1 was defined as the change in HR from the maximum workload to 60 s after the completion of CPET. Oxygen consumption at peak (VO₂@Peak) was defined as the highest 30-s average of oxygen consumption in the last minute of exercise. HR at peak represented the highest HR observed during the exercise protocol. HR at recovery was defined as the value of HR at the moment when exercise stopped. ∆HR was defined as (HR at peak – HR at rest). HR acceleration time was defined as the time taken to increase to 75% of ∆HR (3 min of rest was not included). Slope of increased HR was defined as 75% of ∆HR/HR acceleration time (18).

Definition of BPA Responders and Non-responders
According to the results of reevaluation RHC at follow-up (over 3 months after the last BPA session), patients were categorized as BPA responders or BPA non-responders. In line with previous publications (24), the BPA responders were defined as patients who met one or both of the following criteria: (1) mPAP ≤ 30 mmHg and (2) a reduction of PVR ≥ 30%. Correspondingly, patients with a mPAP > 30 mmHg and a reduction of PVR < 30% at follow-up were categorized as BPA non-responders.

Statistical Analysis
Continuous variables are presented as mean ± standard deviation or median (interquartile range). Categorical variables are given as counts or percentages. Comparison between BPA responders and non-responders were made using an independent-sample t-test, the Mann–Whitney U-test or the Chi-square test, as appropriate. Two-way analyses of variance were used to compare HRR1 at baseline, after the first BPA session and at follow-up with Tukey’s test for multiple comparisons. Correlations between HRR1 and other variables were examined by using Spearman correlation coefficient. The association between baseline HRR1 and BPA outcome was evaluated by using logistic regression model. Univariate logistic regression was firstly performed to identify potential predictors of BPA success. Subsequently, variables with clinical significance or P < 0.100 in univariate analysis were selected for multivariable logistic regression (enter method). Receiver operator characteristic (ROC) curve analysis was performed to determine the optimal cutoff of HRR1 in predicting BPA outcome. A two-sided P < 0.05 was considered statistically significant. Statistical analysis was performed with SPSS 25.0 (IBM SPSS Corp.; Armonk, NY, USA) and Prism GraphPad 8 (GraphPad Software, LaJolla, CA, USA).

RESULTS

Patient Enrollment
One hundred and twenty six patients underwent BPA from May, 2018 to Jan, 2021. Of these patients, 37 were excluded for missing baseline HRR1 data (n = 12), no reevaluation RHC at follow-up (n = 22) and using beta-blockers or other antiarrhythmic agents (n = 3). Among the remaining 89 patients, a total of 206 BPA sessions were performed [2.0 (interquartile range, 1.0–3.0)/per patient], with 1343 subsegmental vessels dilated [14.0 (interquartile range, 7.5–19.0)/per patient]. According to hemodynamics at follow-up, 53 were categorized as BPA responders and 36 patients as BPA non-responders.

Baseline Characteristics
Baseline characteristics of BPA responders and non-responders are summarized in Table 1. Compared with BPA non-responders, responders had lower levels of NT-proBNP, higher HRR1 and underwent more BPA sessions. Of note, mPAP (50.8 ± 11.9 mmHg vs. 51.5 ± 10.9 mmHg, P = 0.861) and PVR (10.2 ± 4.4 wood units vs. 10.0 ± 3.6 wood units, P = 0.855) at baseline were comparable between BPA responders and non-responders.

We also compared baseline characteristics of the included and excluded patients. Both groups were comparable in terms of demographics, exercise capacity, cardiac function and morphology, hemodynamics, and targeted therapy at baseline except higher proportion of WHO FC I/II in the included patients (Supplementary Table 1).

Clinical Assessments at Follow-Up
The clinical status of BPA responders and non-responders at follow-up is presented in Table 2. Like baseline, BPA responders still had higher proportion of WHO FC I/II, lower levels of NT-proBNP, and higher HRR1 at follow-up. More importantly, BPA responders had higher S₆O₂, more favorable echocardiographic parameters [reflected by smaller right ventricular end-diastolic diameter/left ventricular end-diastolic diameter (RVED/LVED), greater left ventricular ejection fraction and lower tricuspid regurgitation velocity], lower VE/VCO₂ slope and better hemodynamics (reflected by higher mixed venous oxygen saturation, lower mPAP, higher cardiac index and lower PVR) than BPA non-responders, even though these variables were comparable at baseline between the two groups. Among BPA responders, 21 achieved a mPAP ≤ 30 mmHg and 4 achieved a mPAP < 25 mmHg.

The Effect of BPA on HRR1
Figure 1 shows that, compared with baseline, HRR1 tended to increase within 7 days after the first BPA session in both BPA responders and non-responders, and this improvement persisted at follow-up.

Correlation Between HRR1 and Well-Validated Markers of CTEPH Severity
As shown in Table 3, HRR1 at baseline and follow-up were associated with NT-proBNP, VO₂@Peak, VE/VCO₂ slope, RVED/LVED, mPAP, and PVR. Furthermore, the absolute change
**TABLE 1 | Baseline characteristics of BPA responders and non-responders.**

| Variables                          | All patients (n = 89) | Responders (n = 53) | Non-responders (n = 36) | P-value* |
|-----------------------------------|-----------------------|---------------------|-------------------------|----------|
| Age, years                        | 58.4 ± 11.6           | 58.0 ± 11.9         | 58.9 ± 11.3             | 0.607    |
| Female, n (%)                     | 47.0 (52.8)           | 28 (52.8)           | 19 (52.8)               | 0.996    |
| Body mass index, kg/m²            | 24.0 ± 3.3            | 24.1 ± 3.4          | 23.7 ± 3.3              | 0.552    |
| WHO FC                            |                       |                     |                         | 0.082    |
| I or II, n (%)                    | 37.0 (41.6)           | 26 (49.1)           | 11 (30.6)               |          |
| III or IV, n (%)                  | 52.0 (58.4)           | 27 (50.9)           | 25 (69.4)               |          |
| NT-proBNP, ng/L                   | 814.0 (195.7, 1780.5) | 497.0 (107.2, 1450.0) | 1052.0 (480.2, 2460)    | **0.019** |
| S\textsubscript{a}O\textsubscript{2}, % | 91.6 ± 3.1            | 91.9 ± 2.7          | 91.2 ± 3.7              | 0.380    |
| 6MWD, m                           | 366.5 ± 110.5         | 381.6 ± 96.0        | 343.9 ± 127.4           | 0.124    |
| Targeted therapy                  |                       |                     |                         | 0.399    |
| None, n (%)                       | 36 (40.4)             | 25 (47.2)           | 11 (30.6)               |          |
| Monotherapy                       |                       |                     |                         |          |
| ERAs, n (%)                       | 6 (6.7)               | 3 (5.7)             | 3 (8.3)                 |          |
| PDE-5is, n (%)                    | 21 (23.6)             | 9 (17.0)            | 12 (33.3)               |          |
| sGCs, n (%)                       | 16 (18.0)             | 8 (15.1)            | 8 (22.2)                |          |
| Combination                       |                       |                     |                         |          |
| ERAs+PDE-5is, n (%)               | 9 (10.1)              | 7 (13.2)            | 2 (5.6)                 |          |
| ERAs+ sGCs, n (%)                 | 1 (1.1)               | 1 (1.9)             | 0                       |          |
| Anticoagulants                    |                       |                     |                         | 0.414    |
| Warfarin, n (%)                   | 57 (64.0)             | 31 (58.5)           | 26 (72.2)               |          |
| Rivaroxaban, n (%)                | 29 (32.6)             | 20 (37.7)           | 9 (25.0)                |          |
| Dabigatran, n (%)                 | 3 (3.4)               | 2 (3.8)             | 1 (2.8)                 |          |
| Echocardiography                  |                       |                     |                         |          |
| LVED, mm                          | 41.0 ± 5.4            | 40.9 ± 5.8          | 41.0 ± 4.9              | 0.621    |
| RVED, mm                          | 32.3 ± 6.2            | 31.7 ± 5.9          | 33.1 ± 6.7              | 0.451    |
| RVED/LVED                         | 0.8 ± 0.2             | 0.8 ± 0.2           | 0.8 ± 0.2               | 0.841    |
| LVEF, %                           | 65.0 ± 5.5            | 65.1 ± 5.8          | 64.9 ± 5.0              | 0.923    |
| TRV, m/s                          | 4.3 ± 0.6             | 4.3 ± 0.7           | 4.4 ± 0.6               | 0.543    |
| Cardiopulmonary exercise test     |                       |                     |                         |          |
| HR at rest, beats/min            | 77.7 ± 13.1           | 77.2 ± 12.2         | 78.5 ± 14.4             | 0.645    |
| HR at peak, beats/min            | 124.3 ± 20.7          | 127.0 ± 19.1        | 120.4 ± 22.5            | 0.140    |
| HR at recovery, beats/min         | 122.8 ± 24.4          | 126.6 ± 19.6        | 117.2 ± 29.5            | 0.076    |
| HRR1, beats                       | 16.0 (10.0, 22.5)     | 17.0 (11.0, 26.5)   | 13.0 (8.0, 17.0)        | **0.018** |
| ΔHRR, beats                       | 46.1 ± 20.1           | 49.8 ± 20.5         | 41.9 ± 18.7             | 0.067    |
| HR acceleration time\textsuperscript{a}, s | 407.9 ± 135.6     | 429.6 ± 111.5        | 376.1 ± 161.1           | 0.068    |
| Slope of increased HR\textsuperscript{b} | 0.09 (0.07, 0.11) | 0.09 (0.07, 0.11) | 0.08 (0.07, 0.11) | 0.701 |
| VO\textsubscript{2}@Peak, mL/min/kg | 12.5 ± 3.5          | 12.8 ± 3.9          | 12.0 ± 2.6              | 0.278    |
| VE/VCO\textsubscript{2} slope     | 49.2 ± 9.5            | 49.1 ± 9.7          | 49.3 ± 9.2              | 0.969    |
| Hemodynamics                      |                       |                     |                         |          |
| S\textsubscript{a}O\textsubscript{2}, % | 69.2 ± 5.2           | 69.9 ± 5.1          | 68.2 ± 5.3              | 0.137    |
| mRAP, mmHg                        | 8.0 (6.0, 9.0)        | 7.8 ± 3.1           | 8.2 ± 3.8               | 0.708    |
| mPAP, mmHg                        | 51.1 ± 11.4           | 50.8 ± 11.9         | 51.5 ± 10.9             | 0.861    |
| PAWP, mmHg                        | 10.0 ± 3.2            | 9.3 ± 3.1           | 10.8 ± 3.3              | 0.050    |
| Cardiac index, L/min/m\textsuperscript{2} | 3.0 ± 0.7           | 3.0 ± 0.7           | 3.0 ± 0.7               | 0.635    |
| PVRI, wood units                  | 10.1 ± 4.1            | 10.2 ± 4.4          | 10.0 ± 3.6              | 0.855    |
| BPA procedure                     |                       |                     |                         |          |
| Number of BPA sessions            | 2.0 (1.0, 3.0)        | 2.0 (1.0, 4.0)      | 2.0 (1.0, 3.0)          | **0.039** |
| Number of dilated subsegmental vessels | 14.0 (7.5, 19.0) | 14.0 (9.0, 22.5) | 12.0 (7.0, 17.0) | 0.115    |
| Time interval\textsuperscript{c}, days | 227.0 (117.0, 422.0) | 287.0 (161.0, 486.5) | 203.5 (100.8, 372.0) | 0.122 |

Data are presented as mean ± standard deviation, median (interquartile range) or number (percentage). BPA, balloon pulmonary angioplasty; ERAs, Endothelin receptor antagonists; HR, heart rate; HRR1, heart-rate recovery at 1 min; LVED, Left ventricular end-diastolic diameter; LVEF, Left ventricular ejection fraction; mPAP, Mean pulmonary arterial pressure; mRAP, Mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAWP, Pulmonary arterial wedge pressure; PDE-5Is, Phosphodiesterase-5 inhibitors; PVRI, Pulmonary vascular resistance; RVED, Right ventricular end-diastolic diameter; 6MWD, 6-min walk distance; sGCs, Soluble guanylate cyclase stimulators; S\textsubscript{a}O\textsubscript{2}, arterial oxygen saturation; S\textsubscript{O}\textsubscript{2}, mixed venous oxygen saturation; TRV, Tricuspid regurgitation velocity; VE/VCO\textsubscript{2} slope, Minute ventilation/carbon dioxide output slope; VO\textsubscript{2}@Peak, Peak oxygen consumption; WHO FC, World Health Organization functional class. \textsuperscript{a}Time interval between baseline and follow-up. \textsuperscript{b}Responders vs. non-responders. \textsuperscript{c}The value of HR at the moment when exercise stopped. \textsuperscript{d}HR at peak minus HR at rest. \textsuperscript{e}The time taken to increase to 75% of ΔHR (min of rest was not included). \textsuperscript{f}The value of HR at the moment when exercise stopped. Bold values mean P < 0.05.
TABLE 2 | Re-assessment of BPA responders and non-responders at follow-up*.

| Variables                  | Responders (n = 53) | Non-responders (n = 36) | P-value |
|----------------------------|---------------------|-------------------------|---------|
| WHO FC                     |                     |                         | 0.023   |
| I or II, n (%)             | 48.0 (90.6)         | 26.0 (72.2)             |         |
| III or IV, n (%)           | 5.0 (9.4)           | 10.0 (27.8)             |         |
| NT-proBNP, ng/L            | 103.0 (56.9, 237.7) | 356.0 (158.2, 800.9)   | 0.001   |
| SpO₂, %                    | 93.7 ± 2.6          | 91.3 ± 6.2              | 0.007   |
| 6MWD, m                    | 436.8 ± 86.2        | 417.3 ± 91.3            | 0.396   |
| Echocardiography           |                     |                         |         |
| LVED, mm                   | 44.4 ± 4.6          | 42.6 ± 4.0              | 0.097   |
| RVED, mm                   | 28.1 ± 4.9          | 30.2 ± 6.4              | 0.089   |
| RV/EVD/LVED                | 0.6 ± 0.1           | 0.7 ± 0.2               | 0.027   |
| LVEF, %                    | 66.4 ± 4.8          | 62.9 ± 5.7              | 0.006   |
| TRV, m/s                   | 3.6 ± 0.7           | 4.2 ± 0.6               | <0.001  |
| Cardiopulmonary exercise test |                 |                         |         |
| HR at rest, beats/min      | 74.7 ± 13.3         | 75.9 ± 11.5             | 0.561   |
| HR at peak, beats/min      | 126.9 ± 18.5        | 121.2 ± 21.0            | 0.155   |
| HR at recovery, beats/min  | 123.6 ± 25.3        | 120.3 ± 20.8            | 0.247   |
| HRR1, beats                | 24 (17.5, 32)       | 20 (13.0, 28.0)         | 0.048   |
| ΔHRR, beats                | 52.2 ± 17.1         | 45.3 ± 18.3             | 0.075   |
| HR acceleration time, s    | 451.3 ± 53.8        | 419.3 ± 115.0           | 0.446   |
| Slope of increased HR²     | 0.09 (0.07, 0.10)   | 0.08 (0.06, 0.10)       | 0.444   |
| VO₂@Peak, ml/min/kg        | 15.0 ± 3.8          | 13.5 ± 3.6              | 0.081   |
| VE/VO₂ slope               | 41.3 ± 7.9          | 45.3 ± 7.6              | 0.025   |
| Hemodynamics               |                     |                         |         |
| SpO₂, %                    | 72.6 ± 4.7          | 69.6 ± 5.7              | 0.007   |
| mRAP, mmHg                 | 6.5 ± 3.0           | 7.0 ± 3.3               | 0.536   |
| mPAP, mmHg                 | 34.9 ± 9.2          | 46.2 ± 10.5             | <0.001  |
| PAWP, mmHg                 | 10.3 ± 3.4          | 9.9 ± 3.6               | 0.567   |
| Cardiac index, L/min/m²    | 3.5 ± 0.9           | 3.1 ± 1.0               | 0.020   |
| PVR, wood units            | 5.1 ± 2.3           | 9.1 ± 3.4               | <0.001  |
| Decrease of mPAP, %        | −31.8 (−39.4)       | −10.8 (−18.8)           | <0.001  |
| Decrease of PVR, %         | −45.3 (−62.0)       | −12.2 (−25.1, 0.1)      | <0.001  |

Data are presented as mean ± standard deviation, median (interquartile range) or number (percentage). BPA, balloon pulmonary angioplasty; HR, heart rate; HRR1, heart-rate recovery at 1 min; LVED, Left ventricular end-diastolic diameter; LVEF, Left ventricular ejection fraction; mPAP, Mean pulmonary arterial pressure; mRAP, Mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAWP, Pulmonary arterial wedge pressure; PVR, Pulmonary vascular resistance; RVED, Right ventricular end-diastolic diameter; 6MWD, 6-min walk distance; Séro, arterial oxygen saturation; SpO₂, Mixed venous oxygen saturation; TRV, tricuspid regurgitation velocity; VE/VO₂ slope, Minute ventilation/carbon dioxide output slope; VO₂@Peak, Peak oxygen consumption; WHO FC, World Health Organization functional class. *Over 3 months after the last BPA session. 1The value of HR at the moment when exercise stopped. 2The time taken to increase to 75% of ΔHRR (3 min of rest was not included). 375% of ΔHRR/HR acceleration time. Bold values mean P < 0.05.

Predictors of BPA Responders

In univariate logistic regression, WHO FC, NT-proBNP, HR at recovery, HRR1, ΔHR, HR acceleration time, PAWP, the number of BPA sessions, the number of dilated subsegmental vessels, and the time interval from baseline to follow-up had a P < 0.100 (Table 4). Age, mPAP and PVR were also included in multivariable logistic regression (enter method) for their clinical significance. The number of dilated subsegmental vessels (r = 0.861, P < 0.001) and the time interval from baseline to follow-up (r = 0.745, P < 0.001) were excluded from multivariable logistic regression for their collinearity with the number of BPA sessions. Variables reflecting HR response to exercise (i.e., HR at recovery, HRR1, ΔHR and HR acceleration time) did not enter multivariable logistic regression simultaneously after consideration of sample size and collinearity. Finally, three to seven independent variables were included in multivariable logistic regression based on the number of events observed (25, 26). In model 1, HRR1 was adjusted for the number of dilated subsegmental vessels and PAWP. In subsequent models, HRR1 was further adjusted for the variables in model 1 plus age, NT-proBNP, WHO FC, mPAP and PVR. In all these 6 multivariable logistic models, HRR1 remained as an independent predictor of BPA responder (Table 5). Similar analysis procedure was also performed for HR at recovery, ΔHR and HR acceleration time. However, no significant association was observed between these variables and BPA outcome (Supplementary Table 2).

Using ROC curve analysis, with the largest sum of sensitivity and specificity chosen, the cutoff value for HRR1 in predicting BPA responders was 19 beats, with an area under the curve of...
TABLE 3 | Correlation between HRR1 and well-validated markers of CTEPH severity.

| Variable                        | HRR1 at baseline | HRR1 at follow-up | ΔHRR1   |
|--------------------------------|-----------------|------------------|---------|
| NT-proBNP at baseline          | *r = −0.422,  \(P < 0.001\) | *r = −0.302, \(P = 0.006\) | *r = −0.225, \(P = 0.049\) |
| NT-proBNP at follow-up         |                 |                  |         |
| ∆NT-proBNP                     |                 |                  |         |
| \(S\text{\textsubscript{a}}O\text{\textsubscript{2}}\) at baseline      | \(r = 0.248, P = 0.019\)   | \(r = 0.172, P = 0.126\)   | \(r = 0.037, P = 0.750\)   |
| \(S\text{\textsubscript{a}}O\text{\textsubscript{2}}\) at follow-up |                 |                  |         |
| ∆\(S\text{\textsubscript{a}}O\text{\textsubscript{2}}\)                |                 |                  |         |
| \(VO\text{\textsubscript{2}}@Peak\) at baseline | \(r = 0.540, P < 0.001\)   | \(r = 0.410, P < 0.001\)   | \(r = 0.293, P = 0.013\)   |
| \(VO\text{\textsubscript{2}}@Peak\) at follow-up |                 |                  |         |
| ∆\(VO\text{\textsubscript{2}}@Peak\) | \(r = 0.540, P < 0.001\)   | \(r = 0.410, P < 0.001\)   | \(r = 0.293, P = 0.013\)   |
| \(VE/VCO\text{\textsubscript{2}}\) slope at baseline | \(r = −0.548, P < 0.001\)  | \(r = −0.481, P < 0.001\)  | \(r = −0.333, P = 0.004\)  |
| \(VE/VCO\text{\textsubscript{2}}\) slope at follow-up |                 |                  |         |
| ∆\(VE/VCO\text{\textsubscript{2}}\) slope                |                 |                  |         |
| \(RV\text{\textsubscript{E}}/LVED\) at baseline | \(r = −0.250, P = 0.018\)   | \(r = −0.261, P = 0.018\)   | \(r = −0.089, P = 0.439\)   |
| \(RV\text{\textsubscript{E}}/LVED\) at follow-up |                 |                  |         |
| ∆\(RV\text{\textsubscript{E}}/LVED\) | \(r = −0.332, P = 0.001\)   | \(r = −0.297, P = 0.007\)   | \(r = −0.134, P = 0.245\)   |
| \(mPAP\) at baseline           | \(r = −0.332, P = 0.001\)   | \(r = −0.297, P = 0.007\)   | \(r = −0.134, P = 0.245\)   |
| \(mPAP\) at follow-up         |                 |                  |         |
| ∆\(mPAP\)                     |                 |                  |         |
| \(PVR\) at baseline           | \(r = −0.412, P < 0.001\)   | \(r = −0.311, P = 0.005\)   | \(r = −0.069, P = 0.557\)   |
| \(PVR\) at follow-up         |                 |                  |         |
| ∆\(PVR\)                     |                 |                  |         |
| Number of BPA sessions         | \(r = 0.411, P < 0.001\)   | \(r = 0.445, P < 0.001\)   | \(r = 0.298, P = 0.008\)   |
| Number of dilated subsegmental vessels | \(r = 0.411, P < 0.001\)   | \(r = 0.445, P < 0.001\)   | \(r = 0.298, P = 0.008\)   |

BPA, balloon pulmonary angioplasty; CTEPH, Chronic thromboembolic pulmonary hypertension; HRR1, heart-rate recovery at 1 min; LVED, Left ventricular end-diastolic diameter; \(L\text{\textsubscript{VE}}\), Left ventricular ejection fraction; mPAP, Mean pulmonary arterial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PVR, Pulmonary vascular resistance; \(R\text{\textsubscript{V}}\text{\textsubscript{E}}\), Right ventricular end-diastolic diameter; \(S\text{\textsubscript{a}}O\text{\textsubscript{2}}, \) arterial oxygen saturation; \(VE/VCO\text{\textsubscript{2}}\) slope, Minute ventilation/ carbon dioxide output slope; \(VO\text{\textsubscript{2}}@Peak\), Peak oxygen consumption. *Time interval between baseline and follow-up. \(\Delta\) means the absolute change of these variables from baseline to follow-up. Bold values mean \(P < 0.05\).

0.643 (95% CI: 0.528–0.758). According to this cutoff value, 30 patients were classified into HRR1 ≥ 19 beats and 59 patients into HRR1 < 19 beats. The number of BPA sessions [median (interquartile range): 2.0 (1.0, 3.0) vs. 2.0 (1.0, 3.0), \(P = 0.561\)], the number of dilated subsegmental vessels [median (interquartile range): 10.5 (7.0, 17.0) vs. 14.0 (9.0, 19.0), \(P = 0.101\)], and the time interval between baseline and reevaluation HRC [median (interquartile range): 267.5 (115.3, 425.3) days vs. 210.0 (115.0, 427.0) days, \(P = 0.801\)] were comparable between patients with HRR1 ≥ 19 beats and < 19 beats. Compared with baseline, mPAP and PVR improved at follow-up in both HRR1 ≥ 19 beats and < 19 beats groups (Figure 2). However, the proportion of BPA responders was significantly higher in patients with HRR1 ≥ 19 beats (80.0% vs. 49.1%, \(P = 0.005\)).

DISCUSSION

The most important finding of our study is that easily available and non-invasive HRR1 is a strong predictor of BPA outcome. Second, we found that HRR1 tended to increase within 7 days after the first BPA session, and this improvement persisted at follow-up, suggesting that BPA could alleviate sympathovagal imbalance. Last, our results showed that improvement in HRR1 was associated with improvement in the well-validated markers of CTEPH severity, indicating that HRR1 might serve as a biomarker which could monitor the efficacy of BPA sessions.

BPA Alleviated Sympathovagal Imbalance

As shown in Figure 1, HRR1 tended to increase within 7 days after the first BPA session and this improvement persisted at follow-up in both BPA responders and non-responders. Similarly, Huo et al. found that the administration of Ambrisentan continuously improved HRR1 in patients with PAH (27). We also found that HRR1 was associated with well-validated markers of CTEPH severity both at baseline and follow-up. More importantly, the change of HRR1 from baseline to follow-up was also correlated with the change of those markers. Therefore, easily available and non-invasive HRR1 might serve as a biomarker which could dynamically monitor the efficacy of BPA sessions.

In healthy subjects, HR is regulated by a sympathovagal balance (28, 29). During exercise, sympathetic activation and parasympathetic withdrawal both contribute to the increase of HR; after peak exercise, sympathetic withdrawal and parasympathetic reactivation both contribute to the recovery of HR (14, 30). Pulmonary hypertension results in right-sided
heart failure, which is a syndrome affecting many organs rather than a condition of pure hemodynamic failure. Previous studies have reported sympathetic hyperactivity and parasympathetic hypoactivity in PAH (9, 31), which is considered as an adaptive mechanism for reduced cardiac output (8). The aforementioned mechanism could also be operational in CTEPH. Thus, it is possible that the impaired HRR1 observed in our study reflected potentially continued sympathetic activation and a lack of normal parasympathetic reactivation after peak exercise. We hypothesized that BPA ameliorated hemodynamics, improved right and left ventricular function, increased cardiac output and then alleviated sympathovagal imbalance (reflected by increased HRR1).

**Baseline HRR1 Predicts the Outcome of BPA**

To date, there is no widely recognized tools for predicting the efficacy of BPA prior to intervention. In the present study, we found that baseline HRR1 was a strong predictor of BPA outcome. Previous studies have demonstrated that both sympathetic hyperactivity and parasympathetic hypoactivity are associated with pulmonary vascular remodeling and right ventricular dysfunction (8, 9, 32). At baseline, BPA non-responders had lower HRR1 than responders, even though hemodynamics were comparable between both groups. At follow-up, BPA non-responders had reasonably worse hemodynamics and still had lower HRR1 than responders. This indicated that, both at baseline and follow-up, BPA non-responders had more severe sympathovagal imbalance than...
responders. We speculated that severe sympathovagal imbalance at baseline (reflected by HRR1 < 19 beats) may increase the tone of pulmonary vasculature to a higher level, which weakens the efficacy of the future BPA sessions. Thus, for BPA non-responders with HRR1 < 19 beats at baseline, transcatheter pulmonary artery denervation might serve as a complementary therapy. Romanov et al. reported that, in patients with residual CTEPH after pulmonary endarterectomy, those underwent transcatheter pulmonary artery denervation had greater improvement in hemodynamics and exercise capacity than those treated with riociguat (13).

It should be stressed that we do not mean to imply that HRR1 < 19 beats is a contraindication for BPA. As shown in Figure 2, mPAP and PVR were also decreased significantly after BPA in patients with HRR1 < 19 beats. Our results should be interpreted as: when undergoing similar amount of BPA sessions and dilating similar amount of subsegmental vessels, the percentage of BPA responders were higher in patients with HRR1 ≥ 19 beats at baseline than that in those with HRR1 < 19 beats at baseline (80% vs. 49.1%, P = 0.005). Another issue is that the number of BPA sessions is relatively small for both BPA-responders and non-responders in the present study. Non-responders may turn into responders in the future BPA sessions. However, this does not undermine the clinical importance of our results. Because clinicians could anticipate that patients with HRR1 ≥ 19 beats at baseline may achieve a more favorable hemodynamic amelioration with less BPA session and lower medical costs than those with HRR1 < 19 beats.

LIMITATIONS

The main limitation of the study is the inherent biases of a retrospective study. Thirty-seven patients were excluded from the study. Nevertheless, we found that the baseline characteristics were comparable between included and excluded patients. Another limitation is that the autonomic function was indirectly assessed by using HRR1 as a surrogate marker in the present study. The interaction between BPA and the autonomic function needs to be further investigated by using gold standard methods such as the measurement of muscle sympathetic nerve activity.

CONCLUSION

BPA could significantly improve HRR1, which indicates the alleviation of sympathovagal imbalance. The change in HRR1 after BPA is associated with the change of well-validated markers of CTEPH severity, which suggests that HRR1 might serve as a biomarker for dynamically monitoring the efficacy of BPA sessions. Baseline HRR1 is a strong independent predictor of BPA outcome.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Fuwai Hospital (Approval No. 2020-1275). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ZL and ZZ contributed to the conception of the study and are guarantors of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article. YZ and XL wrote the manuscript. QZh, QZe, TY, QJ, LY, AD, XM, and CA contributed to data collection. ZL, CX, and QL contributed to the acquisition of funding. All authors critically reviewed the manuscript for intellectual content and had final responsibility for the decision to submit for publication, contributed to data analysis, and interpretation.

FUNDING

This research article was supported by Beijing Municipal Science and Technology Project [Z181100001718200]; Beijing Municipal Natural Science Foundation [7202168]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-12M-C&T-B-055 and 2021-12M-C&T-B-032]; Double First-Class Discipline Construction Fund of Peking Union Medical College and Chinese Academy of Medical Sciences [2019E-XK04-02]; the Capital’s Funds for Health Improvement and Research (CFH) [2020-2-4033 and 2020-4-4035]; and the Youth Fund of Zhongshan Hospital, Fudan University [Grant No. 2021-016].

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.795420/full#supplementary-material

REFERENCES

1. Yan L, Li X, Liu Z, Zhao Z, Luo Q, Zhao Q, et al. Research progress on the pathogenesis of CTEPH. Heart Fail Rev. (2019) 24:1031–40. doi: 10.1007/s10741-019-09802-4
2. Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. (2011) 183:1605–13. doi: 10.1164/rccm.201011-1854CI
3. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. (2019) 53:1915. doi: 10.1183/13993003.01915-2018
4. Galéi N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. (2016) 37:67–119. doi: 10.1093/eurheartj/ehv317
5. Simonneau G, D’Arminio AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. (2015) 45:1293–302. doi: 10.1183/09031936.00087114
6. Mahmud E, Patel M, Ang L, Poch D. Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Pulm Circ. (2021) 11:20458940211007385. doi: 10.1177/20458940211007385
7. Jin Q, Zhao ZH, Luo Q, Zhao Q, Yan L, Zhang Y, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art. World J Clin Cases. (2020) 8:2679–702. doi: 10.29988/wjcc.v8.i13.2679
8. Vaillancourt M, Chia P, Sarji S, Nguyen J, Hofman N, Ruffenach G, et al. Autonomic nervous system involvement in pulmonary arterial hypertension. Respir Res. (2017) 18:201. doi: 10.1186/s12931-017-0679-6
9. da Silva Gonçalves Bós D, Van Der Bruggen CEE, Kurakula K, Sun XQ, Casalli KR, Casalli AG, et al. Contribution of impaired parasympathetic activity to right ventricular dysfunction and pulmonary vascular remodeling in pulmonary arterial hypertension. Circulation. (2018) 137:910–24. doi: 10.1161/CIRCULATIONAHA.117.027451
10. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol. (2013) 62:1092–100. doi: 10.1016/j.jacc.2013.05.075
11. Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Rothman AM, et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. Circ Cardiovasc Inter. (2015) 8:e002837. doi: 10.1161/CIRCINTERVENTIONS.115.002837
12. Zhang H, Zhang J, Chen M, Xie DJ, Kan J, Yu W, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: The PADN-5 Study. JACC Cardiovasc Inter. (2019) 12:274–84. doi: 10.1016/j.jcin.2018.09.021
13. Romanov A, Cherniavskiy A, Novikova N, Edenskly A, Ponomarev D, Shabanov V, et al. Pulmonary artery denervation for patients with residual pulmonary hypertension after pulmonary endarterectomy. J Am Coll Cardiol. (2020) 76:916–26. doi: 10.1016/j.jacc.2020.06.064
14. Pecanha T, Bartels R, Brito LC, Paula-Ribeiro M, Oliveira RS, Goldberger JJ. Methods of assessment of the post-exercise cardiac autonomic recovery: A methodological review. Int J Cardiol. (2017) 227:795–802. doi: 10.1016/j.ijcard.2016.10.057
15. Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. (2012) 185:400–8. doi: 10.1164/rccm.201105-0848OC
16. Ramos RP, Arakaki JS, Barbosa P, Trepтов E, Valois FM, Ferreira EV, et al. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. Am Heart J. (2012) 163:580–8. doi: 10.1016/j.ahj.2012.01.023
17. Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA. Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ. (2015) 5:565–76. doi: 10.1080/20458940.2015.1002432
18. Inagaki T, Terada J, Yahaba M, Kawata N, Jujo T, Nagashima K, et al. Heart rate and oxygen saturation change patterns during 6-min walk test in subjects...
with chronic thromboembolic pulmonary hypertension. *Respir Care.* (2018) 63:573–83. doi: 10.4187/respcare.05788

19. Jin Q, Li X, Zhang Y, Zhao Z, Zhao Q, Yan L, et al. Heart rate recovery at 1 min after exercise is a marker of disease severity and prognosis in chronic thromboembolic pulmonary hypertension. *Respiration.* (2021) 2021:1–10. doi: 10.1159/000520314

20. Jin Q, Luo Q, Yang T, Zeng Q, Yu X, Yan L, et al. Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. *Respir Res.* (2019) 20:250. doi: 10.1186/s12931-019-1211-y

21. Zhang HL, Liu ZH, Wang Y, Xiong CM, Ni XH, He JG, et al. Acute responses to inhalation of iloprost in patients with pulmonary hypertension. *Chin Med J.* (2012) 125:2826–31.

22. Tang Y, Yao L, Liu Z, Xie W, Ma X, Luo Q, et al. Peak circulatory power is a strong prognostic factor in patients with idiopathic pulmonary arterial hypertension. *Respir Med.* (2018) 135:29–34. doi: 10.1016/j.rmed.2018.01.003

23. Tang Y, Luo Q, Liu Z, Ma X, Zhao Z, Huang Z, et al. Oxygen uptake efficiency slope predicts poor outcome in patients with idiopathic pulmonary arterial hypertension. *J Am Heart Assoc.* (2017) 6:5037. doi: 10.1161/JAHA.116.005037

24. Taniguchi Y, Brenot P, Jais X, Garcia C, Weatherald J, Planche O, et al. Poor subpleural perfusion predicts failure after balloon pulmonary angioplasty for nonoperable chronic thromboembolic pulmonary hypertension. *Chest.* (2018) 154:521–31. doi: 10.1016/j.chest.2018.03.059

25. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol.* (1996) 49:1373–9. doi: 10.1016/0895-4356(96)00236-3

26. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol.* (2007) 165:710–8. doi: 10.1093/aje/kwm052

27. Huo Y, Jing ZC, Zeng XF, Liu JM, Yu ZX, Zhang GC, et al. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study. *BMC Cardiovasc Disord.* (2016) 16:201. doi: 10.1186/s12872-016-0361-9

28. Goldberger JJ. Sympathovagal balance: how should we measure it? *Am J Physiol.* (1999) 276:H1273–80. doi: 10.1152/ajpheart.1999.276.4.H1273

29. Ng J, Sundaram S, Kadish AH, Goldberger JJ. Autonomic effects on the spectral analysis of heart rate variability after exercise. *Am J Physiol Heart Circ Physiol.* (2009) 297:H1421–8. doi: 10.1152/ajpheart.00217.2009

30. Imai K, Sato H, Horii M, Kusuoka H, Ozaki H, Yokoyama H, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. *J Am Coll Cardiol.* (1994) 24:1529–35. doi: 10.1016/0735-1079(94)90150-3

31. Velez-Roa S, Ciarka A, Njem B, Vachier JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. *Circulation.* (2004) 110:1308–12. doi: 10.1161/01.CIR.0000140724.90898.D3

32. Mercurio V, Pellegrino T, Bosso G, Campi G, Parrella F, Piscopo V, et al. EXPRESS: cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure. *Pulm Circ.* (2019) 9:2045894019868620. doi: 10.1177/2045894019868620

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Li, Luo, Zhao, Zeng, Yang, Jin, Yan, Duan, Ma, An, Xiong, Zhao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.